Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
28th February 2019

Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications

13th February 2019

Avedro Announces Pricing of Initial Public Offering

11th February 2019

IFM Therapeutics Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases

4th February 2019

GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

1st February 2019

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

30th January 2019

Beckman Coulter Life Sciences Acquires Labcyte To Expand Laboratory Automation Business

14th January 2019

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

8th January 2019

Pixium Vision announces its wireless PRIMA chip successfully met the interim study endpoints for dry Age-related Macular Degeneration

4th January 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

3rd January 2019

Gynesonics Announces $75 Million Financing

3rd January 2019

AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39

3rd January 2019

Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in Cancer